就实论事 | 歪曲抹黑终难敌科学与真相

Hi, I’m Einar Tangen. Welcome to Reality Check. The Western traditional and social media narrative is that China was unprepared to begin its co-existence with COVID. These are the same groups, that 40 days ago, were demanding that China immediately reverse its COVID containment strategy, on economic and humanitarian grounds, or face economic and political collapse. 

大家好，我是艾那·唐根，欢迎关注《就实论事》。西方传统媒体和社交媒体上充斥着所谓中国并没做好“与病毒共存”准备的言论。正是这伙人，40天前还在以经济和人道主义为由，要求中国立即转变疫情防控政策，并称如若不然 中国将面临经济和政治崩溃。

China’s government earned stellar marks, in terms of the people’s support for its actions. As complied by a slew of independent international surveys, that put confidence in the central government between the high 80s to 95 percent, since 2020. So what is the reality?

中国政府的执政能力，获得了中国民众的高支持率。众多独立开展的国际民调显示，自2020年以来中国民众对中央政府的信任度保持在高区位的80%到95%之间。那么事实到底如何呢？

“We were the first to promise to make COVID-19 vaccines a global public product, the first to support intellectual property exemptions for vaccine research and development, and the first to cooperate with developing countries in vaccine production. We have supplied more than 2.2 billion doses of COVID-19 vaccines to more than 120 countries and international organizations,” said Mi Feng, Spokesman for the China’s National Health Commission.

国家卫生健康委新闻发言人米锋：“我们最早承诺将新冠疫苗作为全球公共产品，率先支持疫苗研发知识产权豁免，最早同发展中国家开展疫苗生产合作。已向120多个国家和国际组织供应超过22亿剂新冠疫苗。”

In fact, half of the vaccines administered over the last 3 years were from Chinese manufacturers, who were willing to go the extra step, by creating joint ventures to manufacture vaccines in other countries. A stark contrast to most of the developed nation manufacturers who refused to share or reduce prices for their vaccines.

事实上在过去三年中 全球使用的新冠疫苗中一半是由中国制造。中国积极推动疫苗出海，与多国开展疫苗联合生产，而大多数发达国家疫苗厂商的做法却截然不同，他们拒绝疫苗共享，也不降低其疫苗价格。

The recent release of 60,000 deaths, fully, or partially, attributable to COVID has stunned the doubters, who were forecasting a million or more deaths.

中国近期公布了在院新冠感染相关死亡病例近6万例，这令怀疑论者感到难以置信，他们曾预测中国死亡人数会超百万。

“A total of 59,938 deaths related to COVID-19 occurred in hospitals nationwide, from Dec. 8, 2022 to Jan. 12, 2023. Of these 5,503 died due to respiratory failure, caused by COVID-19, 54,435 died due to underlying issues complicated by COVID-19. The average age at the time of death was 80.3 years. About 90.1 percent  of those were over 65, 56.5 percent, being for those over 80,” said Jiao Yahui, Head of the Bureau of Medical Administration, under the National Health Commission.

国家卫健委医政司司长焦雅辉：“从2022年12月8日到2023年1月12日，全国医疗机构累计发生在院新冠病毒感染相关死亡病例59938例，其中新冠病毒感染导致呼吸功能衰竭死亡病例5503例，基础疾病合并新冠病毒感染死亡病例54435例，死亡病例平均年龄80.3岁，65岁及以上约占90.1%，其中80岁及以上约占56.5%。”

So how has China been able to deal with COVID better than developed nations with more resources? Simply through basing its policies on science and pragmatic implementation. 

那么，中国为何能够比拥有更多医疗资源的发达国家更好地应对疫情挑战？答案在于科学决策，扎实推进。

In terms of science, China shared the complete genome sequence of the novel coronavirus on January 11, a little less than a month after it had been identified. It had taken over a year to do it in 2002 during the first SARS outbreak. By October 2022, 46 COVID-19 vaccines were in human trials in China, and over 20 were in overseas clinical trials. These included: three inactivated monovalent vaccines, designed to neutralize Omicron variants; three domestically-developed mRNA-based COVID-19 broad-spectrum vaccines; an oral inhalation vaccine that has already been approved for emergency use as a booster. So far, 13 COVID-19 vaccines have been developed and been given conditional market approval or greenlighted for emergency use in China. Recent agreements have opened the market for a number of outside approaches as well.

就防疫工作的科学性而言，中国在2020年1月11日便向全世界分享了新型冠状病毒的完整基因组序列，当时距该病毒被发现才不到一个月时间。2002年“非典”期间 病毒基因组测序工作耗时一年多才完成。截至2022年10月，已有46种新冠疫苗在中国进行临床试验，超过20种在海外进行临床试验。这其中包括三款中和奥密克戎变异株的灭活疫苗，目前正在中国内地 香港特区和阿联酋开展序贯免疫试验，三款国产mRNA广谱疫苗，还有一款吸入式疫苗已获准作为加强针紧急使用。目前中国已有13款国产新冠疫苗获批附条件上市或获准紧急使用。近期签署的多项协议也允许国外多款新冠治疗药物进入中国市场。

 In terms of pragmatic implementation, China with 1.4 billion people, has, considering the logistics involved, been extremely effective. In the end, the truth will be reflected in the numbers. When the total excess deaths and disabilities are calculated and compared country by country, 6 months from now, China’s handling of COVID can be compared apples to apples with other countries.

鉴于中国14亿的人口规模，其中涉及大量保障工作，就扎实推进而言，可以说是相当高效。不久的将来，数据会告诉我们真相。从现在起的6个月里，按国别计算和比较超额死亡和残障总数，便可对中国的疫情防控成效与其他国家进行公正的比较。

 So as you read through the latest criticism of China’s handling of COVID, you might do well to think about the facts and ignore the spin, especially when it comes to measuring how your government handled COVID.

因此，当你看到批评中国防疫政策的报道时，最好能够参考客观事实，不要理会那些带节奏的言论，特别是在衡量你们的政府应对疫情成效几何的时候。

推荐阅读：